Published in Circulation on June 04, 2002
Effect of PCSK9 InhibitorS On Calcific Aortic Valve DiseasE (EPISODE) | NCT04968509
Human aortic valve calcification is associated with an osteoblast phenotype. Circulation (2003) 4.49
Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol (2007) 3.96
Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol (2006) 2.95
Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the Heart and Soul Study. Circulation (2007) 2.23
Lowering plasma cholesterol levels halts progression of aortic valve disease in mice. Circulation (2009) 2.20
The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am J Pathol (2007) 2.18
Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation (2005) 1.88
Calcific aortic valve stenosis: methods, models, and mechanisms. Circ Res (2011) 1.70
Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart (2005) 1.65
Molecular imaging insights into early inflammatory stages of arterial and aortic valve calcification. Circ Res (2011) 1.62
Role for circulating osteogenic precursor cells in aortic valvular disease. Arterioscler Thromb Vasc Biol (2011) 1.61
Identification and characterization of aortic valve mesenchymal progenitor cells with robust osteogenic calcification potential. Am J Pathol (2009) 1.55
Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation. Eur Heart J (2010) 1.46
Diseases of Wnt signaling. Rev Endocr Metab Disord (2006) 1.36
Calcific aortic stenosis: lessons learned from experimental and clinical studies. Arterioscler Thromb Vasc Biol (2008) 1.31
The regulation of valvular and vascular sclerosis by osteogenic morphogens. Circ Res (2011) 1.29
Calcified rheumatic valve neoangiogenesis is associated with vascular endothelial growth factor expression and osteoblast-like bone formation. Circulation (2005) 1.18
Calcific aortic stenosis: from bench to the bedside--emerging clinical and cellular concepts. Heart (2003) 1.18
Targeted therapy to prevent progression of calcific aortic stenosis. Circulation (2004) 1.17
Bisphosphonate Use and Prevalence of Valvular and Vascular Calcification in Women MESA (The Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol (2010) 1.12
Retracted C-reactive protein in aortic valve disease. Cardiovasc Ultrasound (2006) 1.12
C-reactive protein in degenerative aortic valve stenosis. Cardiovasc Ultrasound (2006) 1.11
Role of the MAPK/ERK pathway in valvular interstitial cell calcification. Am J Physiol Heart Circ Physiol (2009) 1.08
Uraemic hyperparathyroidism causes a reversible inflammatory process of aortic valve calcification in rats. Cardiovasc Res (2008) 1.06
Cellular mechanisms of aortic valve calcification. Circ Cardiovasc Interv (2012) 1.03
Differential proteoglycan and hyaluronan distribution in calcified aortic valves. Cardiovasc Pathol (2010) 1.01
Interaction of age with lipoproteins as predictors of aortic valve calcification in the multi-ethnic study of atherosclerosis. Arch Intern Med (2008) 1.00
Serotonin receptors and heart valve disease--it was meant 2B. Pharmacol Ther (2011) 0.99
Osteopontin promoter polymorphism is associated with increased carotid intima-media thickness. J Am Soc Echocardiogr (2008) 0.97
Atorvastatin decreases cellular proliferation and bone matrix expression in the hypercholesterolemic mitral valve. J Am Coll Cardiol (2005) 0.97
A computational model of aging and calcification in the aortic heart valve. PLoS One (2009) 0.95
Smoothelin-positive cells in human and porcine semilunar valves. Histochem Cell Biol (2003) 0.92
The role of Lrp5/6 in cardiac valve disease: LDL-density-pressure theory. J Cell Biochem (2011) 0.92
Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS. J Cardiovasc Magn Reson (2008) 0.90
Bicuspid aortic valve disease: the role of oxidative stress in Lrp5 bone formation. Cardiovasc Pathol (2011) 0.90
Calcific aortic stenosis: a disease ready for prime time. Circulation (2006) 0.89
Animal models of calcific aortic valve disease. Int J Inflam (2011) 0.88
ACE inhibition attenuates uremia-induced aortic valve thickening in a novel mouse model. BMC Cardiovasc Disord (2009) 0.88
The role of Lrp5/6 in cardiac valve disease: experimental hypercholesterolemia in the ApoE-/- /Lrp5-/- mice. J Cell Biochem (2011) 0.87
Defining the role of fluid shear stress in the expression of early signaling markers for calcific aortic valve disease. PLoS One (2013) 0.87
Oxidative-mechanical stress signals stem cell niche mediated Lrp5 osteogenesis in eNOS(-/-) null mice. J Cell Biochem (2012) 0.87
Left-sided cardiac valvulitis in tristetraprolin-deficient mice: the role of tumor necrosis factor alpha. Am J Pathol (2010) 0.87
In vitro models of aortic valve calcification: solidifying a system. Cardiovasc Pathol (2014) 0.86
Myxomatous mitral valve disease bench to bedside: LDL-density-pressure regulates Lrp5. Expert Rev Cardiovasc Ther (2014) 0.86
Mechanisms of aortic valve calcification: the LDL-density-radius theory: a translation from cell signaling to physiology. Am J Physiol Heart Circ Physiol (2009) 0.85
Pathogenesis of aortic stenosis: not just a matter of wear and tear. Am J Cardiovasc Dis (2011) 0.85
Quantitative cardiovascular magnetic resonance for molecular imaging. J Cardiovasc Magn Reson (2010) 0.84
Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation. Vasc Health Risk Manag (2011) 0.83
Visualizing novel concepts of cardiovascular calcification. Trends Cardiovasc Med (2013) 0.83
Evaluation of the prevalence of coronary artery disease in patients with valvular heart disease. J Cardiothorac Surg (2014) 0.82
Raloxifene attenuates Gas6 and apoptosis in experimental aortic valve disease in renal failure. Am J Physiol Heart Circ Physiol (2011) 0.82
Association of interleukin-1 beta (-511C/T) polymorphisms with osteoporosis in postmenopausal women. Ann Saudi Med (2010) 0.81
Mechanisms of calcification in aortic valve disease: role of mechanokinetics and mechanodynamics. Curr Cardiol Rep (2013) 0.79
Diagnosis and management of patients with asymptomatic severe aortic stenosis. World J Cardiol (2016) 0.78
Is it time for medical therapy for aortic valve disease? Expert Rev Cardiovasc Ther (2004) 0.77
Calcific Aortic Valve Disease: Molecular Mechanisms and Therapeutic Approaches. Eur Cardiol (2015) 0.77
Modified lipoprotein-derived lipid particles accumulate in human stenotic aortic valves. PLoS One (2013) 0.77
Effect of hydroxymethylglutaryl coenzyme-a reductase inhibitors on the long-term progression of rheumatic mitral valve disease. Circulation (2010) 0.76
Medical therapy for rheumatic heart disease: is it time to be proactive rather than reactive? Indian Heart J (2009) 0.76
Serum phosphate concentrations: a novel pre-clinical biomarker for cardiovascular calcification. J Am Coll Cardiol (2011) 0.76
Role of serum high density lipoprotein levels and functions in calcific aortic valve stenosis progression. Int J Clin Exp Med (2015) 0.75
Histopathological assessment of calcification and inflammation of calcific aortic valves from patients with and without diabetes mellitus. Histol Histopathol (2016) 0.75
Is there a role of statins in the prevention of aortic biological prostheses degeneration. Cardiovasc Ultrasound (2006) 0.75
Risk factor profile of calcific aortic stenosis. Indian Heart J (2016) 0.75
Role for Galectin-3 in Calcific Aortic Valve Stenosis. J Am Heart Assoc (2016) 0.75
Cellular Changes during Renal Failure-Induced Inflammatory Aortic Valve Disease. PLoS One (2015) 0.75
Therapeutic Effect and Mechanism of Action of Abnormal Savda Munziq in Development of Degenerative Atherosclerotic Aortic Valve Disease. Med Sci Monit (2017) 0.75
Effect of Rosuvastatin on Bovine Pericardial Aortic Tissue Valve Calcification in a Rat Subdermal Implantation Model. Korean Circ J (2017) 0.75
Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell (1997) 18.91
Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell (1997) 16.78
Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol (1997) 7.45
Bone formation and inflammation in cardiac valves. Circulation (2001) 6.01
Increased bone formation in osteocalcin-deficient mice. Nature (1996) 4.91
The osteoblast: a sophisticated fibroblast under central surveillance. Science (2000) 3.93
Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol (1997) 2.80
Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation (2001) 2.60
Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol (1996) 2.60
Phosphate is a specific signal for induction of osteopontin gene expression. Proc Natl Acad Sci U S A (2000) 2.59
Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis (1999) 2.56
Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation (2001) 2.55
Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation (2001) 2.17
Isolation and characterization of osteoblast precursor cells from human bone marrow. J Bone Miner Res (1996) 2.16
Cardiovascular features of homozygous familial hypercholesterolemia: analysis of 16 patients. Am J Cardiol (1984) 1.99
C-reactive protein is increased in patients with degenerative aortic valvular stenosis. J Am Coll Cardiol (2001) 1.72
Detection and quantitation of calcific atherosclerosis by ultrafast computed tomography in children and young adults with homozygous familial hypercholesterolemia. Arterioscler Thromb (1994) 1.58
Cbfa1 as a regulator of osteoblast differentiation and function. Bone (1999) 1.58
Molecular cloning and characterization of 2B7, a rat mRNA which distinguishes smooth muscle cell phenotypes in vitro and is identical to osteopontin (secreted phosphoprotein I, 2aR). Biochem Biophys Res Commun (1991) 1.48
HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol (1998) 1.45
Detection of osteopontin in calcified human aortic valves. Arterioscler Thromb Vasc Biol (1997) 1.41
Experimental hypercholesterolemia induces apoptosis in the aortic valve. J Heart Valve Dis (2001) 1.10
Digital image analysis. Mayo Clin Proc (1995) 1.02
Watanabe rabbits with heritable hypercholesterolaemia: a model of atherosclerosis. Histol Histopathol (1998) 1.00
Cell proliferation after balloon injury of iliac arteries in the cholesterol-fed New Zealand White rabbit. Arterioscler Thromb (1994) 0.98
Bone acidic glycoprotein-75 is a major synthetic product of osteoblastic cells and localized as 75- and/or 50-kDa forms in mineralized phases of bone and growth plate and in serum. J Biol Chem (1990) 0.97
Characteristics of macrophage-derived foam cells isolated from atherosclerotic lesions of rabbits. Atherosclerosis (1997) 0.84
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 23.07
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 17.18
Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med (2011) 10.29
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 8.90
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 8.01
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2014) 7.41
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol (2004) 6.50
Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation (2011) 6.36
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation (2006) 4.61
Human aortic valve calcification is associated with an osteoblast phenotype. Circulation (2003) 4.49
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2014) 4.34
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care (2007) 4.30
2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2014) 4.20
Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation (2007) 4.16
Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med (2005) 4.16
Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology (2007) 3.85
2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg (2014) 3.59
The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. J Thorac Cardiovasc Surg (2007) 3.45
A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab (2003) 3.25
Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol (2012) 3.24
Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation (2003) 3.22
Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol (2013) 3.15
Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (2002) 3.14
Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc (2007) 3.12
Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology (2007) 3.08
Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care (2004) 3.00
Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol (2006) 2.95
Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation (2010) 2.94
Obstructive coronary atherosclerosis and ischemic heart disease: an elusive link! J Am Coll Cardiol (2012) 2.93
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2014) 2.91
Is hospital admission for heart failure really necessary?: the role of the emergency department and observation unit in preventing hospitalization and rehospitalization. J Am Coll Cardiol (2013) 2.89
Endurance exercise as a countermeasure for aging. Diabetes (2008) 2.83
Symptom presentation of women with acute coronary syndromes: myth vs reality. Arch Intern Med (2007) 2.70
Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology (2003) 2.61
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol (2006) 2.57
A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol (2005) 2.56
Racial and ethnic differences in the treatment of acute myocardial infarction: findings from the Get With the Guidelines-Coronary Artery Disease program. Circulation (2010) 2.53
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2011) 2.53
Reproducibility of chronic infarct size measurement by contrast-enhanced magnetic resonance imaging. Circulation (2002) 2.40
STICH (Surgical Treatment for Ischemic Heart Failure) trial enrollment. J Am Coll Cardiol (2010) 2.39
Liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of estradiol and estrone in human plasma. Clin Chem (2003) 2.38
Centrin-2 is required for centriole duplication in mammalian cells. Curr Biol (2002) 2.37
Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J (2004) 2.29
Prevalence of regional myocardial thinning and relationship with myocardial scarring in patients with coronary artery disease. JAMA (2013) 2.29
Angiographic estimates of myocardium at risk during acute myocardial infarction: validation study using cardiac magnetic resonance imaging. Eur Heart J (2007) 2.26
Tension between quality measurement, public quality reporting, and pay for performance. JAMA (2013) 2.19
Insights from the STICH trial: change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction. J Thorac Cardiovasc Surg (2012) 2.10
Navigating the crossroads of coronary artery disease and heart failure. Circulation (2006) 2.06
Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. J Clin Oncol (2010) 2.06
Statin use and lower extremity amputation risk in nonelderly diabetic patients. J Vasc Surg (2013) 2.05
Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol (2005) 2.00
Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation (2003) 1.99
Prosthesis-patient mismatch in bovine pericardial aortic valves: evaluation using 3 different modalities and associated medium-term outcomes. Circ Cardiovasc Imaging (2013) 1.97
The effects of aerobic exercise on glucose and counterregulatory hormone concentrations in children with type 1 diabetes. Diabetes Care (2006) 1.95
The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res (2009) 1.94
The E3 ubiquitin ligase Itch regulates expression of transcription factor Foxp3 and airway inflammation by enhancing the function of transcription factor TIEG1. Nat Immunol (2008) 1.91
Simultaneous determination of 12 steroids by isotope dilution liquid chromatography-photospray ionization tandem mass spectrometry. Clin Chim Acta (2006) 1.89
Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation (2007) 1.89
Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation (2005) 1.88
Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J Clin Endocrinol Metab (2003) 1.77
Expression of lipoprotein-associated phospholipase A(2) in carotid artery plaques predicts long-term cardiac outcome. Eur Heart J (2009) 1.77
Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERalpha or ERbeta. J Cell Biochem (2003) 1.76
Left ventricular function during and after right ventricular pacing. J Am Coll Cardiol (2004) 1.74
Screening for coronary artery disease in patients with diabetes. Diabetes Care (2007) 1.72